Vascular protective effects by activation of nuclear receptor PPARγ

详细信息    查看全文

• 作者：Wakino ; Shu ; Law ; Ronald E. ; Hsueh ; Willa A.
• 关键词：PPARγ ; diabetes ; cell cylce ; atherosclerosis
• 刊名：Journal of Diabetes and its Complications
• 出版年：2002
• 出版时间：January - February, 2002
• 年：2002
• 卷：16
• 期：1
• 页码：46-49
• 全文大小：105 K

文摘

Pharmaceutical interventions targeting proteins that regulate VSMC growth and movement are promising new approach to treat diabetes-associated cardiovascular disease. Peroxisome proliferator-activated receptor-γ (PPARγ) is a ligand-activated transcription factor in the nuclear receptor superfamily. Thiazolidineodione (TZT) insulin sensitizers are pharmacologic ligands for PPARγ. All of the major cells in the vasculature express PPARγ, including endothelial cells. VSMCs, and monocytes/macrophages. PPARγ ligands may protect the vasculature against injury by inhibiting cell growth and movement, improving endothelial function, and suppressing tissue inflammation. Antiproliferative effects of PPARγ ligands are mediated by targeting critical cell cycle regulators, including Rb and p27^Kip1, that regulate the progression of cells from G1 phase into S phase to conduct DNA synthesis. Pharmacologic activation of PPARγ in vascular cells may provide a novel therapeutic approach to retard diabetes-associated vascular disease.